Nifty Pharma Slips By 500 Points; All Stocks In Red
By Shishta Dutta | Updated at: Jan 7, 2026 01:45 PM IST
Mumbai, June 17 (2:40 PM IST): The Nifty Pharma index witnessed broad-based selling pressure on Tuesday, falling 2.27% or 500.05 points to 21,539.40 as of 2:40 PM IST, with 20 out of 20 stocks trading in the red. Weak sentiment across the broader market, with the Nifty 50 also down 0.40%, weighed on the healthcare pack.
The Nifty Pharma index tracks key pharmaceutical and healthcare companies listed on the National Stock Exchange (NSE). It includes major players such as Sun Pharma, Dr. Reddy’s, Cipla, Biocon, and Divi’s Labs. The index is an indicator of investor sentiment in India’s healthcare sector.
Index Performance: As of 2:40 PM IST
| Metric | Value |
|---|---|
| Previous Close | 22,039.45 |
| Open | 22,029.15 |
| Day High | 22,057.15 |
| Day Low | 21,695.40 |
| Last Price | 21,539.40 |
| Change | -500.05 |
| % Change | -2.27% |
| 52-Week High | 23,907.90 |
| 52-Week Low | 19,121.10 |
| Traded Volume | 1.66 crore |
| Traded Value | ₹1,615 crore |
The selloff follows a 1.88% gain over the past 30 days, but investor appetite appears to have cooled ahead of key global events and institutional rebalancing cues.
Top Losers (as of 2:40 PM IST)
| Company | Price (₹) | % Change | YoY Return |
|---|---|---|---|
| Aurobindo Pharma | 1,106.20 | -3.42% | -9.02% |
| Granules India | 500.50 | -2.94% | +11.67% |
| Lupin | 1,956.00 | -2.73% | +25.36% |
| Natco Pharma | 880.45 | -2.43% | -25.46% |
| Sun Pharma | 1,649.70 | -2.11% | +11.17% |
Sector Overview
The sharp 2.27% drop in Nifty Pharma reflects broad profit booking amid global uncertainties and institutional rebalancing. All 20 stocks ended in the red, led by losses in Aurobindo and Granules. Weak global cues, valuation concerns, and muted earnings outlook added to the pressure. Short-term volatility may persist, but long-term fundamentals remain strong.
What Does This Mean for the Investors?
For investors, the sharp decline in the Nifty Pharma index suggests a short-term shift in sentiment driven by global uncertainty and institutional rebalancing. While this may trigger caution, long-term investors can view it as a potential buying opportunity in quality pharma stocks, especially given the sector’s strong fundamentals and growth prospects. Patience and stock-specific selection remain key.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
